Journal
GLIA
Volume 59, Issue 8, Pages 1205-1212Publisher
WILEY
DOI: 10.1002/glia.21137
Keywords
glioma; kinase inhibitors; angiogenesis
Categories
Funding
- National Cancer Institute [U54CA143798-01, U01 CA141502]
- American Society of Clinical Oncology
- Doris Duke Charitable Foundation
- Leon Levy Foundation
Ask authors/readers for more resources
Detailed characterization of the cancer genome in a large number of primary human glioblastomas has identified recurrent alterations that result in deregulation of signal transduction pathways and are druggable with a growing number of small molecule pharmaceuticals. While many of these compounds have shown clinical activity in other human cancers harboring similar genetic alterations, the clinical experience in glioblastoma has been disappointing thus far with only rare and transient radiographic responses. Our understanding of drug resistance is confounded by the uncertainty of drug delivery across the blood brain barrier and the limited knowledge to what extent the growth of these tumors depends on any particular signaling pathway. This uncertainty is, at least in part, due to shortcomings in the current approach to evaluate signal transduction inhibitors in glioma patients, including drug testing in molecularly unselected patient populations, limited documentation of drug penetration and target inhibition in tumor tissue, and use of radiographic response criteria that may not be optimal for the evaluation of these compounds. (C) 2011 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available